Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$23.90
+0.2%
$19.67
$16.10
$41.94
$3.01B0.782.85 million shs1.54 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$195.98
+0.0%
$174.87
$111.09
$199.99
$11.98B0.41535,961 shs803,613 shs
Moderna, Inc. stock logo
MRNA
Moderna
$25.66
+0.7%
$29.19
$23.15
$91.99
$9.91B1.838.26 million shs12.21 million shs
QIAGEN N.V. stock logo
QGEN
QIAGEN
$48.98
+2.0%
$48.15
$37.63
$51.88
$10.67B0.641.62 million shs1.34 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-2.13%-1.69%+22.69%+38.02%-35.56%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+2.34%+6.42%+12.01%+21.33%+54.34%
Moderna, Inc. stock logo
MRNA
Moderna
-2.49%-7.85%-24.29%-0.08%-70.01%
QIAGEN N.V. stock logo
QGEN
QIAGEN
-0.01%-4.49%-0.24%+14.10%+8.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.643 of 5 stars
4.33.00.04.42.72.50.6
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.641 of 5 stars
3.52.00.00.03.31.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.3649 of 5 stars
4.01.00.04.62.92.50.6
QIAGEN N.V. stock logo
QGEN
QIAGEN
3.4798 of 5 stars
1.12.01.74.52.01.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.58
Moderate Buy$34.1242.75% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$239.8022.36% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$43.5969.87% Upside
QIAGEN N.V. stock logo
QGEN
QIAGEN
2.27
Hold$49.691.44% Upside

Current Analyst Ratings Breakdown

Latest APLS, QGEN, MRNA, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$289.00 ➝ $295.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$243.00 ➝ $290.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$210.00 ➝ $230.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$306.00 ➝ $307.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$212.00 ➝ $220.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $203.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$212.00 ➝ $254.00
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$48.00 ➝ $50.00
8/4/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$35.00 ➝ $37.00
(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$781.37M3.86N/AN/A$1.24 per share19.27
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M30.45N/AN/A($3.48) per share-56.32
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.09N/AN/A$24.16 per share1.06
QIAGEN N.V. stock logo
QGEN
QIAGEN
$1.98B5.50$3.27 per share14.98$15.77 per share3.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%N/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$5.16N/A816.58N/A-54.94%N/A-24.31%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%N/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$83.59M$1.6928.9419.912.4518.30%14.77%8.87%N/A

Latest APLS, QGEN, MRNA, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million
8/5/2025Q2 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.60$0.60N/A$0.44$523.97 million$533.54 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/31/2025Q2 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.51%N/A14.79%N/A

Latest APLS, QGEN, MRNA, and ASND Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.52%7/2/20257/3/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.90
3.77
3.16
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.02
0.69
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.25
1.61
1.35

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
QIAGEN N.V. stock logo
QGEN
QIAGEN
70.00%

Insider Ownership

CompanyInsider Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6.80%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
QIAGEN N.V. stock logo
QGEN
QIAGEN
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770126.29 million117.70 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01761.15 million36.69 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable
QIAGEN N.V. stock logo
QGEN
QIAGEN
5,765222.29 million202.29 millionOptionable

Recent News About These Companies

William Blair Forecasts Qiagen's Q2 Earnings (NYSE:QGEN)
QIAGEN (NYSE:QGEN) Downgraded by Wall Street Zen to "Buy"
Qiagen (NYSE:QGEN) Cut to Buy at Wall Street Zen
William Blair Has Optimistic Outlook of Qiagen Q1 Earnings
Qiagen (NYSE:QGEN) Issues FY 2025 Earnings Guidance
Qiagen (NYSE:QGEN) Issues Q3 2025 Earnings Guidance
Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript
A Look at Qiagen's Upcoming Earnings Report
Qiagen (QGEN) Matches Q2 Earnings Estimates

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$23.90 +0.05 (+0.21%)
Closing price 04:00 PM Eastern
Extended Trading
$23.86 -0.04 (-0.15%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$195.98 +0.01 (+0.01%)
Closing price 04:00 PM Eastern
Extended Trading
$195.91 -0.07 (-0.04%)
As of 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Moderna stock logo

Moderna NASDAQ:MRNA

$25.66 +0.19 (+0.75%)
Closing price 04:00 PM Eastern
Extended Trading
$25.78 +0.13 (+0.49%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

QIAGEN stock logo

QIAGEN NYSE:QGEN

$48.98 +0.97 (+2.02%)
Closing price 03:59 PM Eastern
Extended Trading
$48.96 -0.02 (-0.04%)
As of 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.